Monica Mead

1.0k total citations
34 papers, 427 citations indexed

About

Monica Mead is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Monica Mead has authored 34 papers receiving a total of 427 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 14 papers in Pathology and Forensic Medicine and 7 papers in Genetics. Recurrent topics in Monica Mead's work include CAR-T cell therapy research (17 papers), Lymphoma Diagnosis and Treatment (13 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Monica Mead is often cited by papers focused on CAR-T cell therapy research (17 papers), Lymphoma Diagnosis and Treatment (13 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Monica Mead collaborates with scholars based in United States, Italy and Japan. Monica Mead's co-authors include Sara A. Hurvitz, Amanda Davis, Anthony J. Viera, Sarah M. Larson, John M. Timmerman, Gary J. Schiller, Patricia A. Young, Eric H. Yang, Mirela Tuzovic and J.C. Foreman and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Monica Mead

31 papers receiving 423 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Monica Mead United States 9 165 154 90 88 55 34 427
Andrea Kühnl United Kingdom 11 207 1.3× 306 2.0× 106 1.2× 112 1.3× 57 1.0× 34 632
Anna Brandt Germany 9 243 1.5× 138 0.9× 62 0.7× 99 1.1× 109 2.0× 17 470
Diederik van Bodegom United States 7 101 0.6× 185 1.2× 42 0.5× 40 0.5× 57 1.0× 10 360
Huirong Ding China 11 110 0.7× 173 1.1× 51 0.6× 44 0.5× 57 1.0× 23 376
Victor Yazbeck United States 12 165 1.0× 220 1.4× 160 1.8× 31 0.4× 55 1.0× 34 472
Jessica Boklan United States 12 118 0.7× 215 1.4× 20 0.2× 134 1.5× 59 1.1× 30 467
Yuanfei Shi China 11 97 0.6× 375 2.4× 43 0.5× 53 0.6× 38 0.7× 26 488
Joanna Stachura Poland 11 99 0.6× 155 1.0× 70 0.8× 16 0.2× 55 1.0× 21 417
László Márkász Sweden 10 184 1.1× 107 0.7× 38 0.4× 34 0.4× 121 2.2× 23 379
Liping Fan China 10 89 0.5× 243 1.6× 39 0.4× 28 0.3× 75 1.4× 34 407

Countries citing papers authored by Monica Mead

Since Specialization
Citations

This map shows the geographic impact of Monica Mead's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Monica Mead with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Monica Mead more than expected).

Fields of papers citing papers by Monica Mead

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Monica Mead. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Monica Mead. The network helps show where Monica Mead may publish in the future.

Co-authorship network of co-authors of Monica Mead

This figure shows the co-authorship network connecting the top 25 collaborators of Monica Mead. A scholar is included among the top collaborators of Monica Mead based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Monica Mead. Monica Mead is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zinzani, Pier Luigi, Eric D. Jacobsen, Jasmine Zain, et al.. (2024). Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial. Blood. 144(Supplement 1). 3061–3061. 4 indexed citations
2.
Timmerman, John M., Patricia A. Young, Herbert Eradat, et al.. (2024). Survival benefit of autologous transplant (ASCT) for mantle cell lymphoma (MCL) in the California Cancer Registry (CCR).. Journal of Clinical Oncology. 42(16_suppl). e19043–e19043.
3.
Rojek, Alexandra E., Nausheen Ahmed, Sairah Ahmed, et al.. (2024). CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium. Blood. 144(Supplement 1). 4503–4503.
4.
Song, Justin, Jacqueline Vuong, Monica Mead, et al.. (2024). Abstract 4138101: CAR-T-associated Cardiovascular Events are Associated with Increased Resource Utilization. Circulation. 150(Suppl_1).
5.
Timmerman, John M., Patricia A. Young, Caspian Oliai, et al.. (2023). Deliriogenic Medication Use in Older Adults Receiving CAR-T Correlates with Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Blood. 142(Supplement 1). 7358–7358. 1 indexed citations
6.
Mehta–Shah, Neha, Pier Luigi Zinzani, Jasmine Zain, et al.. (2023). Duvelisib in patients with relapsed/refractory peripheral T‐cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: outcomes by baseline histology. Hematological Oncology. 41(S2). 499–500. 6 indexed citations
7.
Mead, Monica, et al.. (2023). The role of transplantation in Hodgkin lymphoma. Frontiers in Oncology. 12. 1054314–1054314. 5 indexed citations
8.
Larson, Sarah M., Christopher M. Walthers, Jacob Naparstek, et al.. (2022). CD19/CD20 bispecific chimeric antigen receptor (CAR) in naïve/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma.. Journal of Clinical Oncology. 40(16_suppl). 2543–2543. 6 indexed citations
9.
Schiller, Gary J., Sven de Vos, Herbert Eradat, et al.. (2021). Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience. Clinical Lymphoma Myeloma & Leukemia. 21(12). 861–872. 17 indexed citations
10.
Brammer, Jonathan E., Pier Luigi Zinzani, Jasmine Zain, et al.. (2021). Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis. Blood. 138(Supplement 1). 2456–2456. 15 indexed citations
11.
12.
13.
Walthers, Christopher M., Jacob Naparstek, Monica Mead, et al.. (2020). Phase I Dose-Escalation Trial of CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) T-Cells for the Treatment of Relapsed or Refractory B-Cell Lymphomas and Chronic Lymphocytic Leukemia. Blood. 136(Supplement 1). 19–20. 4 indexed citations
14.
Pro, Barbara, Jonathan E. Brammer, Carla Casulo, et al.. (2020). Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial Results. Blood. 136(Supplement 1). 38–39. 8 indexed citations
15.
Tuzovic, Mirela, Monica Mead, Patricia A. Young, Gary J. Schiller, & Eric H. Yang. (2019). Cardiac Complications in the Adult Bone Marrow Transplant Patient. Current Oncology Reports. 21(3). 28–28. 27 indexed citations
16.
Larson, Sarah M., Monica Mead, Andrae Vandross, et al.. (2017). Abstract 136: Phospho-S6 levels correlate with response to Copanlisib (BAY 80-6946) in multiple myeloma. Cancer Research. 77(13_Supplement). 136–136. 1 indexed citations
17.
Cao, Qi, Micah D. Gearhart, Sigal Gery, et al.. (2016). BCOR regulates myeloid cell proliferation and differentiation. Leukemia. 30(5). 1155–1165. 66 indexed citations
18.
Hurvitz, Sara A. & Monica Mead. (2015). Triple-negative breast cancer. Current Opinion in Obstetrics & Gynecology. Publish Ahead of Print(1). 59–69. 86 indexed citations
19.
Davis, Amanda, Anthony J. Viera, & Monica Mead. (2014). Leukemia: an overview for primary care.. PubMed. 89(9). 731–8. 81 indexed citations
20.
Piotrowski, W., Monica Mead, & J.C. Foreman. (1987). Action of the SP2–11 and SP3–11 fragments of substance P on rat peritoneal mast cells. Inflammation Research. 20(3-4). 178–180. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrea Kühnl Breakdown of academic impact, for papers by Anna Brandt Breakdown of academic impact, for papers by Diederik van Bodegom Breakdown of academic impact, for papers by Huirong Ding Breakdown of academic impact, for papers by Victor Yazbeck Breakdown of academic impact, for papers by Jessica Boklan Breakdown of academic impact, for papers by Yuanfei Shi Breakdown of academic impact, for papers by Joanna Stachura Breakdown of academic impact, for papers by László Márkász Breakdown of academic impact, for papers by Liping Fan
Rankless by CCL
2026